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Summary F-18 ﬂuorodeoxyglucose positron emission tomography is now part of the initial
stage III and IV cancer work-up and each time that metastasis or the presence of a second cancer
is suspected that may contraindicate major surgery. Similarly, this exam should be undertaken
when the conventional work-up is negative but there is isolated metastatic adenopathy. In
therapeutic follow-up, a 3- or 4-month delay must be respected to prevent false-positive exams
caused by inﬂammation. Although FDG-PET seems very promising in determining target volumes
in radiotherapy, its implementation raises a number of problems that can only be resolved
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ositron emission tomography (PET) imaging has proved
ts worth in the management of head and neck cancer,
oth at the initial stage, exploring locoregional and remote
xtension, and during treatment.
This article reviews the main indications for PET scan,
ocusing especially on its role in determining target volumes
n radiotherapy.
ole in initial assessmenthe diagnostic role of 18-ﬂuorodeoxyglucose (18FDG) PET
n head and neck cancer is limited: its sensitivity is similar
o that of anatomic imaging, at 88—100% [1—3], and its
∗ Corresponding author. Tel.: +(00-33)-1 56 09 27 18.
E-mail address: marc.faraggi@egp.aphp.fr (M. Faraggi).
r
g
t
i
[
t
a
879-7296/$ – see front matter © 2010 Published by Elsevier Masson SAS
oi:10.1016/j.anorl.2010.02.010of the different specialists.
sson SAS.
peciﬁcity is impaired by the fact that inﬂammatory lesions
nd benign tumors may also be 18FDG-avid. Quantiﬁcation
echniques such as Standardized Uptake Value (SUV) have
ailed to live up to the hopes of determining potential
umor aggressiveness. 18FDG-PET thus fails to replace
iopsy and conventional imaging, which moreover more
ccurately evaluate the anatomic relationship between
umor, neighboring structures and tissue inﬁltration.
Its enhanced sensitivity (75—91%) [1—4] compared to
natomic imaging, on the other hand, makes 18FDG-PET of
ndeniable interest for determining locoregional ganglion
nvolvement (Figs. 1 and 2) [3,5]. Its contribution to staging
etropharyngeal adenopathy [6], the ﬁrst link in the gan-
lionic chain in some 5% of cases [6], needs interpreting in
he light of conventional and especially MRI ﬁndings [7], but
18t seems clear that adding FDG-PET enhances performance
8,9].
18FDG-PET suffers from false positives and false nega-
ives. False positives are essentially due to inﬂammatory
nd/or infectious phenomena, macrophage and lymphocyte
.
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Figure 1 50-year-old male smoker, presenting with swallowing impaired for several months and group IIa left adenopathy. Left: 3D-
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tPET images; middle: transverse PET slice (top) and frontal PET s
18FDG-PET found a hypermetabolic left pyriform sinus lesion (P
carcinoma, with ipsilateral group II and III adenopathies (LN). M
cells being natural uptakers of 18FDG. False negatives corre-
late less to the size of the adenopathy itself than to that of
the metastatic process, as lymph node micrometastases may
fail to show up on 18FDG-PET images [3,10]. Large zones of
acellular necrosis or lymph node proximity to the primitive
tumor may also lead to false negatives.
Indications for 18FDG-PET should take account of the clin-
ical context and the probability of lymph node involvement,
which varies greatly from cancer to cancer: it is present
when the tumor is ﬁrst discovered in 60—80% of nasopharyn-
geal cancers, and its probability increases with tumor size
(especially for sizes T2 or greater). In tumors with less lymph
node involvement, such as tumor of the glottis, and in small
tumors, where lymph node involvement is mostly revealed
as micrometastasis by the pathologist, 18FDG-PET is of less
interest.
18FDG-PET allows full-body imaging, giving it a major role
in screening for remote loci or a second cancer, which might
contraindicate heavy surgery such as total laryngectomy.
This is particularly useful for centimetric pulmonary lesions
undetected on standard check-up [3]. Given the frequency
of associated metastasis, 18FDG-PET is mandatory in N3—4
tumors. Remote metastasis is also common in rhinopha-
ryngeal cancer. Metachronous or secondary cancer should
be screened for systematically in cancer associated with
alcohol or nicotine dependence [10]. Even so, PET ﬁndings
beneﬁt from comparison with anatomic imaging results [7].
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Pbottom); right: corresponding CT slices with fused PET images.
orresponding to a well-differentiated keratinizing epidermoid
lar tongue tip ﬁxation is physiological.
ole in treatment
ancer patients with non-operable locoregional extension or
n whom an organ needs to be conserved currently undergo
adiochemotherapy. PET ﬁndings should therefore be stud-
ed in deciding upon such a strategy.
ole in determining radiotherapy target volumes
linical implementation of conformational radiotherapy
nd intensity-modulated radiation therapy (IMRT) requires
he most rigorous determination of the volume of target
umors (to deliver the maximum effective dose) and of
t-risk organs (to be protected). The tumor volumes to be
etermined are the Gross Tumor Volume (GTV), on the basis
f which the Clinical Target Volume (CTV) and Planning
arget Volume (PTV) are determined, with allowance for a
ertain safety margin. Until recently, GTV was determined
rom anatomic imaging (CT and MRI). The modern PET cam-
ra now enables a metabolic dimension to be added and
he real effective dose to be approximated. Standardized
adiotherapy tables can be ﬁtted to the PET camera, and
hanks to accurate laser-assisted positioning tumor volume
an be determined on the metabolic images with the patient
ositioned as in radiotherapy. Moreover, the new-generation
ET/CT scanner, including latest generation CT, provides
42 M. Duet et al.
Figure 2 41-year-old male with alcohol and nicotine abuse, admitted for staging of a left tonsil lesion and a right IIa adenopathy.
Left to right: (left) frontal PET slice showing the large IIa adenopathy (LN) and another smaller (previously unknown) underlying one;
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[center) transverse PET slice through tonsils (top) and frontal s
evealed not only the previously detected left tonsil lesion, but a
esponsible for the right IIa adenopathies. Histology conﬁrmed
ontrast-enhanced millimetric scans of diagnostic quality,
ombining anatomic and metabolic GTV values. Organ
onservation strategies thus require a patient-management
etwork of ENT surgeons, radiotherapists, radiologists and
uclear medicine physicians relying no longer on CT or on
ET alone but on combined CT—PET exploration.
However attractive this methodology may be in theory,
mplementation still runs up against a certain number of
ractical problems.
There are discrepancies between the ‘‘anatomic’’ and
‘metabolic’’ GTV values for the primitive tumor, the latter
ending to be smaller [11—13]. The metabolic GTV, more-
ver, is not systematically contained within the anatomic
TV: there are often segments included in the anatomic
ut not the metabolic GTV, and vice versa. Several studies
13—15] stress that incorporating PET data in determining
TV signiﬁcantly changes the resultant value and con-
ouring, and hence the provisional dose. Metabolic GTV
etermination is still by no means standardized and a
ariety of thresholds have been recommended, so that
natomic data cannot yet be dispensed with in deter-
ining target volume. In a recent study [16], however,
ecurrences all lay within not only the anatomic but
lso the metabolic GTV, which was of almost half the
ize.
T
Tbottom); (right) idem, on fused PET/CT images. FDG-PET/CT
contralateral hypermetabolic tonsil lesion (red cross) probably
ll-differentiated epidermoid carcinoma at this second site.
Tumor reduction and changes in anatomic structure dur-
ng radiochemotherapy affect real volumes and hence dose
istribution. Some authors therefore recommend adjusting
TV values during the course of radiochemotherapy, gen-
rally before the ﬁnal boost [11,12]. Such reassessment
ould seem to be best made on conventional imaging,
s treatment-induced inﬂammation unduly increases 18FDG
ptake zones at this stage, which is thus too early for PET
canning.
A more innovatory development is to take account
f tumor hypoxia, which is now possible using hypoxia
racers, the oldest and most widely used of which is
8Fluoro-Misonidazole (FMISO). Although the hypoxic tumor
olume is signiﬁcantly smaller than the hypermetabolic
umor volume, which in turn is smaller than the anatomic
TV, several studies have highlighted the prognostic value
f maximum hypoxia tracer uptake, and recommend asso-
iating radiosensitizers and/or treatment intensiﬁcation
17].reatment efﬁcacy assessment
wo treatment phases are to be considered:
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• distinguishing responders and non-responders as of ini-
tiation of chemotherapy could avoid unduly heavy
treatment, in both human and ﬁnancial terms, targeting
therapy more efﬁciently;
• after termination of chemo/radiotherapy, it is essential to
detect residual mass viability. Given the poor prognosis,
intensiﬁcation is logically to be considered in advanced
non-operable forms, when 18FDG uptake remains elevated
at end of treatment [18], and if intensiﬁcation is allowed
by clinical status.
While it is currently recommended not to perform a
neck dissection on N1-grade adenopathy unless response
is incomplete, controversy remains in the case of N2 and
N3 adenopathy showing complete response. Certain authors
recommend systematic neck dissection; others consider
PET/CT sufﬁciently predictive for neck dissection to be use-
ful only in case of incomplete response, which would reduce
indications by more than 75%, at the cost of underestimat-
ing residual pathology in 2% of cases [19,20]. Consensus may
yet be reached thanks to more sensitive techniques, such
as that of the sentry ganglion, which could be applied in
PET-negative patients.
Ongoing treatment efﬁcacy assessment
Certain authors [21] have shown, in various types of tumor,
that very early assessment of efﬁcacy, as of the ﬁrst
chemotherapy cycles, is of prognostic value. Reduced 18FDG
uptake, assessed on SUV after the ﬁrst courses, corre-
lates with the percentage of early remission, although with
response differences from one tumor to another one even in
a given patient, conﬁrming the concept of tumoral hetero-
geneity.
Assessment should be at least 2weeks after the end
of a chemotherapy cycle. Yen et al. [22], in a series of
50 nasopharyngeal carcinoma patients, showed that PET
performed 1 to 2weeks after the end of the ﬁrst (n = 33)
or second (n = 17) chemotherapy induction course was of
predictive value, over a mean 50.9± 16.1month follow-
up: only one of 23 responders relapsed versus 15 of the
27 non-responders. The authors also reported no signiﬁcant
difference in survival according to whether imaging was per-
formed after the ﬁrst or the second course.
No adequate cohort studies, however, have assessed the
impact of early PET scanning in chemoradiotherapy.
End of treatment efﬁcacy assessment
18FDG-PET is especially relevant here as conventional
(CT/MRI) imaging is hindered by ﬁbrotic remodeling
secondary to surgery or radiotherapy, preventing differen-
tial diagnosis between residual mass and local recurrence.
To optimize performance, an interval of 3 to 4 months should
be left after the end of chemoradiotherapy [18] to avoid
false positives induced by inﬂammatory phenomena, notably
due to radionecrosis within the tumor and neighboring tis-
sue. The rate of false positives decreases with increasing
interval, and can be further reduced by careful reading of
the images and, of course, by using combined PET/CT data.
It is to be borne in mind that attempts at SUV quantiﬁcation
and at determining a threshold to distinguish residual can-
cer from inﬂammation have been disappointing [18]. While
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ET scanning should not be performed in the middle of an
nﬂammatory period following chemoradiotherapy, too long
n interval would hinder management, complicating any
econdary surgery linked to the presence of ﬁbrosis and scar
issue.
Conversely, too early determination after the end of
reatment may induce false negatives due to the small size
f the recurrence and to irradiated cell behavior. After
rradiation, cells either die or remain quiescent before cell-
ycle reactivation, and tracer uptake is reduced during this
uiescent phase; subsequent increase in tumor volume and
esumed cell activity enable later detection.
Under optimal conditions as described above, and despite
weak positive predictive value (at 50—80%), PET exami-
ation is highly effective [23,24], with 94% head and neck
ecurrence detection sensitivity and excellent negative pre-
ictive values for both local recurrence (97%) and remote
ocations (98%). Performance is identical in head and neck
quamous cell carcinoma (HNSCC) and undifferentiated car-
inoma of nasopharyngeal type (UCNT). Negative predictive
alue seems to be 15—22% better than on conventional CT
nd/or MRI imaging [25].
rimitive tumor exploration in isolated
etastatic cervical adenopathy
he percentage of primitive tumors undetected on
raditional exploration in isolated metastatic cervical
denopathy is estimated at 3—7% [26]. In this indication,
8FDG-PET shows better sensitivity than conventional
maging. This is partly because metabolic changes come
arlier than anatomic ones, and partly because PET can
etect lesions smaller than its spatial resolution if they
re highly hypermetabolic [27]. In a review of 302 patients
eported on between 1994 and 2003, Rusthoven et al. [28]
ound that PET discovered a primitive tumor in almost 25%
f cases in which it had gone undetected on conventional
maging (CT/MRI) or panendoscopy.
The causes of false positives need to be known in
rder to minimize them. The physiological ﬁxation sites
f the aero-digestive system, such as the lymphoid tissue
Waldeyer’s ring) should be known and taken into account
n interpreting results. The patient must be instructed
ot to speak, chew or swallow after 18FDG injection, to
imit laryngeal and pharyngeal muscle hyper-uptake. Biopsy
nd surgery procedures (such as tonsillectomy, which is
ometimes systematic) can induce inﬂammatory reactions,
isturbing PET as well as conventional imaging.
In conclusion, 18FDG-PET is useful only when other diag-
ostic tests show negative. A positive PET ﬁnding, on the
ther hand, requires conﬁrmation by biopsy, due to the high
ate of false positives. It is to be borne in mind that 10% of
atients have tumors outside of the ENT zone (lung, esoph-
gus, etc.) [29].
onclusionhe present review of the literature combined with our own
xperience indicates that 18FDG-PET is currently essential
o initial assessment of grade III and IV tumors, and when-
ver remote dissemination or a second tumor is suspected,
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ontraindicating heavy surgery. Likewise, 18FDG-PET should
e performed in case of negative conventional results
or isolated metastatic adenopathy. During follow-up, a
- to 4-month interval after termination of treatment is
andatory in order to optimize prognostic value. 18FDG-PET
eems to be of real interest in determining radiotherapy
arget volumes, but implementation still raises problems
hich only close cross-disciplinary teamwork can resolve.
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